Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05503095
Other study ID # IT-VA-237-2021
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date January 1, 2022
Est. completion date May 31, 2024

Study information

Verified date October 2023
Source Maastricht University Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Protein convertase subtilisin/kexin type 9 (PCSK9) plays a regulatory role in cholesterol homeostasis by promoting low-density lipoprotein receptor (LDLr) degradation. Although the vast majority of the studies have focused on the role of PCSK9 in LDLr expression in the liver, an increasing body of evidence suggests that PCSK9 gene is also present in extra-hepatic tissues. A recent publication showed for the first time that PCSK9 is expressed in the ischemic heart and the expression is highest in the zone bordering the infarcted areas. Furthermore, the expression of PCSK9 is maximal early, at 1 week of ischemia. Mechanical complications (or cardiac ruptures) are uncommon but potentially lethal sequelae of acute myocardium infarction (AMI) and are commonly associated with early mortality without appropriate surgical intervention. It's unknown why some patients develop these devasting complications following AMI, while others not. Interestingly, studies have shown that post-infarction cardiac rupture affect the border zone between the ischemic and normal area and occur within the first 3 to 5 days after AMI. Based on the aforementioned observations, it's likely to assume a relationship between PCSK9 expression and the development of post-AMI cardiac rupture. Therefore, the main purpose of the this project is to study the PCSK9 gene polymorphism and its association with cardiac rupture. Investigators hypothesize that PCSK9 expression/secretion and development of post-AMI cardiac rupture may be a part of the dynamic changes at cellular levels occurring in the ischemic heart of genetically predisposed patients.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date May 31, 2024
Est. primary completion date August 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - clinical diagnosis of acute myocardial infarction with ST sopra-elevation (control group) - clinical diagnosis of acute myocardial infarction complicated by cardiac rupture Exclusion Criteria: - absence of coronary artery disease

Study Design


Intervention

Genetic:
Genetic analysis for PCSK9 polymorphisms
Determination of PCSK9 gene polymorphism and serum PCSK9 concentration

Locations

Country Name City State
Italy Matteo Matteucci Varese

Sponsors (1)

Lead Sponsor Collaborator
Maastricht University Medical Center

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary PCSK9 gene polymorphism PCSK9 gene polymorphism (studied at patient admission and recovery for acute myocardial infarction) up to 1 year
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04735913 - Effects of Metabolic Enzymes and Transporter Gene Polymorphisms on the Pharmacokinetics and Metabolism of Oral Abiraterone Acetate in Healthy Chinese Adults Early Phase 1
Recruiting NCT06431789 - Prospective Observational Association Between SLCO1B1 Gene Polymorphism and the Anti-factor Xa Activity of Edoxaban in Patients With Moderate to Severe Renal Insufficiency
Completed NCT05380128 - Association Study Between VDR Gene Polymorphisms and Risk and Features of MG in Han Chinese Population
Recruiting NCT04960774 - Risk Factors for Severe Periodontitis in 30 to 40 Year Olds: a Retrospective Study